47th International Liver Congress

(EASL 2012)

April 18-22, 2012, Barcelona

EASL 2012: Telaprevir 100% Effective for IL28B CC, Adding VX-222 Overcomes Unfavorable Genes

Adding telaprevir (Incivek) to pegylated interferon and ribavirin cured all hepatitis C patients with the favorable IL28B gene pattern, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona. Another study found that adding the experimental HCV polymerase inhibitor VX-222 raised cure rates even for those with unfavorable IL28B patterns.

alt

Read more:

EASL 2012: Ribavirin Dose Reduction Is Effective for Managing Anemia in Patients Using Boceprevir or Telaprevir

Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th International Liver Congress (EASL 2012) this week in Barcelona. A related study found that ribavirin reduction also did not impair cure rates with telaprevir (Incivek).alt

Read more:

EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon

Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap

Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

EASL 2012: MicroRNA Miravirsen Looks Safe and Effective for Genotype 1 Hepatitis C

Miravirsen, the first microRNA therapy for hepatitis C, was well-tolerated and demonstrated prolonged antiviral activity lasting past the end of dosing in a proof-of-concept study of previously untreated HCV genotype 1 patients presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more: